Gwt-tud Gmbh
Clinical trials sponsored by Gwt-tud Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug may cut transfusions for MDS patients Results expected Oct 2026 (estimated)
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control CompletedThis study tested a combination of three drugs (pomalidomide, ixazomib, and dexamethasone) with or without a fourth drug (cyclophosphamide) in 66 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how well the treatment control…
Phase 2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo therapy shows promise in tough pancreatic cancer
Disease control CompletedThis study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…
Phase 1/2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC